金沙娱城手机app下载

Providing innovative and affordable medicines
for all patients

Supported by our strong talent base and our fully integrated R&D platform, we have developed, and continued to expand a comprehensive product pipeline of multiple late-stage biologics candidates and bio-innovative drugs, with significant potential for a variety of PD-1/PD-L1 based immuno-oncology combination therapies.


Until now, we have completed IND/CTA filings of 13 products and 2 combination therapies with 23 indications and obtained 29 successful IND/CTA approvals (19 approvals from mainland China; 3 from the United States; 3 from Taiwan, China; each 1 from the European Union, Ukraine, Philippines and Australia). HLX01 (rituximab injection), our first product, has been granted approval by the NMPA as the first approved biosimilar in China. Moreover, HLX03 has received a New Drug Application (NDA) acceptance from NMPA.

Intellectual Property
Relevant
Products
Patent Name Patent Holder Patent Number Jurisdiction of
Registration
Application
Date
Expiry Date
HLX01 HLX02 HLX03 HLX04 Kit for detecting DNA residues of CHO cell and using method thereof Henlius ZL201110066745.4 PRC 2011-03-18 2031-03-17
HLX01 HLX02 HLX03 HLX04 Method for detecting DNA content of CHO cells by probe Henlius ZL201110099204.1 PRC 2011-04-20 2031-04-19
HLX06 Anti-Vascular endothelial growth factor receptor 2 (VEGFR2) antibodies Henlix PCT/US2016/040183 PRC, the U.S.,
the EU, Canada,
Australia, India,
South Africa, Brazil,
Russia, Japan, Korea
2016-06-29 2036-06-29
HLX07

Anti-Epidermal growth factor receptor (EGFR) antibodies


Anti-Epidermal growth factor receptor (EGFR) antibodies

Henlix

Henlix
PCT/US2015/033402

TW104117520

PRC, the U.S., the EU, Australia, Japan, Korea

Taiwan China

2015-05-29

2015-05-29
2035-05-29

2035-05-29
HLX10

Anti-PD-1 Antibodies


Anti-PD-1 Antibodies

Henlius; Henlix

Henlius; Henlix
PCT/US2017/050851

TW106131824

PCT

(Patent Cooperation Treaty)

Taiwan China

2017-09-09

2017-09-15
2037-09-09

2037-09-15
HLX20

Anti-PD-L1 Antibodies and variants


Anti-PD-L1 Antibodies and variants

Henlius; Henlix

Henlius; Henlix
PCT/US2017/056689

TW106137352

PCT

(Patent Cooperation Treaty)

Taiwan China

2017-10-14

2017-10-30
2037-10-14

2037-10-30
Publications
Baidu
sogou